Doravirine/lamivudine/tenofovir disoproxil fumarate - Merck & Co

Drug Profile

Doravirine/lamivudine/tenofovir disoproxil fumarate - Merck & Co

Alternative Names: DELSTRIGO; MK-1439/lamivudine/tenofovir disoproxil fumarate; MK-1439A

Latest Information Update: 12 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck Sharp & Dohme
  • Developer Merck Sharp & Dohme; National Institute of Allergy and Infectious Diseases
  • Class Antiretrovirals; Deoxyribonucleosides; Dideoxynucleosides; Nitriles; Phosphonic acids; Purines; Pyridones; Pyrimidine nucleosides; Small molecules; Triazoles
  • Mechanism of Action Non-nucleoside reverse transcriptase inhibitors; Nucleoside reverse transcriptase inhibitors; Nucleotide reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Registered HIV-1 infections

Most Recent Events

  • 04 Oct 2018 Adverse events and efficacy data from the phase III DRIVE_SHIFT trial in HIV-1 infections released by Merck
  • 04 Oct 2018 Additional efficacy and adverse events data from the phase III DRIVE-AHEAD trial in HIV-1 infections released by Merck
  • 20 Sep 2018 Committee for Medicinal Products for Human Use recommends approval of doravirine/lamivudine/tenofovir disoproxil fumarate for HIV-1 infections (Treatment-naive) in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top